Krystal Biotech advances KB407 with positive CF trial data

Krystal Biotech ( (KRYS) ) just unveiled an update.

On January 8, 2026, Krystal Biotech reported positive interim results from the highest-dose cohort of its Phase 1 CORAL-1 study of KB407 in cystic fibrosis patients, confirming successful delivery and expression of wild-type CFTR protein in conducting airway cells via inhalation across both modulator-eligible and modulator-ineligible patients, with 29.4% to 42.1% of conducting airway cells transduced in those with successful bronchoscopies and all suitable biopsies showing CFTR or viral marker expression. KB407 was generally well tolerated at the highest dose, with adverse events mostly mild to moderate and one procedure-related serious adverse event resolving within five days, and, on the back of these molecular and safety findings, Krystal has submitted the design of its repeat-dosing, registrational-intent CORAL-3 study to the FDA, targeting alignment on the protocol in early 2026 and enrollment beginning in the first half of 2026, a step that could significantly advance its competitive position in CF gene therapy and offer a potential disease-modifying option for patients who cannot benefit from current modulators.

The most recent analyst rating on (KRYS) stock is a Buy with a $309.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Spark’s Take on KRYS Stock

According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.

Krystal Biotech’s strong financial performance and successful international expansion are the most significant factors driving the stock’s positive outlook. The company’s robust earnings call and strategic corporate events further bolster confidence. However, technical indicators suggest caution due to potential short-term overbought conditions, and the high valuation reflects expectations of continued growth.

To see Spark’s full report on KRYS stock, click here.

More about Krystal Biotech

Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing genetic medicines, including inhaled gene therapies, for serious diseases such as cystic fibrosis, with an emphasis on mutation-agnostic approaches that can serve patients who are ineligible for or underserved by existing CFTR modulator treatments.

Average Trading Volume: 294,888

Technical Sentiment Signal: Buy

Current Market Cap: $7.23B

Learn more about KRYS stock on TipRanks’ Stock Analysis page.